"Growing adoption of EPO biomarkers for the treatment of aids, neurological, and haematological diseases, is driving the market growth"
According to the OMR analysis, the global EPO biomarkers Market is expected to grow impressively during 2018-2023. The global EPO biomarkers market is segmented on the basis of biomarker type, applications, and end users. The report provides detailed and insightful chapters on market overview, key findings, strategic recommendations, market estimations, market determinants, sector analysis, key company analysis, market insights, company profiling, market segmentation, geographical analysis, analyst insights, and predictive analysis of the market.
The global EPO biomarkers market has witnessed a steady growth due to increasing illness of chronic illnesses such as cancer and kidney disorder and a favorable reimbursement policy has increased the demand for EPO biomarkers. Moreover, growing adoption of EPO biomarkers for the treatment of AIDS, neurological, hematological, and end-stage renal diseases is fueling the growth of the global EPO biomarkers market. According to the statistics provided by the World Health Organization (WHO), around 50 million people are suffering from epilepsy, making it one of the most common neurological diseases across the globe. On the basis of biomarker type, the global EPO biomarkers market is segmented into six broad categories, namely, erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, recombinant human erythropoietin, and darbepoetin alfa. The erythropoietin alfa EPO biomarker is estimated to hold the largest share in the global EPO biomarker market due to its increased adoption in the treatment of cancer and other end-stage renal diseases.
Global EPO biomarkers market by region is segmented into North America, Europe, Asia-Pacific, and rest of the world. Asia-Pacific is expected to exhibit the fastest growth in the near future due to increasing prevalence of hematological diseases in the region, especially in India, China, Pakistan, and Bangladesh. The presence of local EPO biomarker manufacturers along with the low cost of treatment therapy are some of the major factors that are significantly contributing in the market growth. North America holds a dominant position in the global EPO biomarkers market in 2017, owing to favorable reimbursement policies and improved healthcare infrastructure in the region. Furthermore, the rising acceptance for bio-similar is another factor that is significantly contributing in the market growth.
The report covers:
Comprehensive research methodology of global EPO biomarkers market
This report also includes detailed and extensive market overview with key analyst insights
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
Analysis of regional regulations and other government policies impacting the global EPO biomarkers market
Insights about market determinants which are stimulating the global EPO biomarkers market
Detailed and extensive market segments with regional distribution of forecasted revenues
Extensive profiles and recent developments of market players
About Orion Market Research
Orion Market Research (OMR) is an Indian research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company provides quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations, and detailed company profiles.
For more information, visit: https://www.omrglobal.com/industry-reports/epo-biomarkers-market/